abiraterone,olaparib
astrazeneca,merck
['propel', 'gu ', 'merck', 'astrazeneca']
astrazeneca and merck present final results of key secondary overall survival endpoint from phase iii propel trial at asco gu cancers symposium 
Breaking news from Business Wire